The Technical Analyst
Galecto, Inc. [GLTO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Galecto, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.35% $0.682
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18.48 mill |
| EPS: | -1.440 |
| P/E: | -0.470 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 27.11 mill |
| Avg Daily Volume: | 0.228 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.470 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.470 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.798 (17.16%) $0.117 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.637 - 0.771 ( +/- 9.52%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-03 | Schambye Hans T. | Buy | 200 000 | Restricted Stock Units |
| 2024-01-03 | Winslow Garrett | Buy | 100 000 | Restricted Stock Units |
| 2024-01-03 | Freve Jonathan | Buy | 100 000 | Restricted Stock Units |
| 2023-08-15 | Orbimed Advisors Llc | Sell | 535 534 | Common Stock |
| 2023-08-15 | Orbimed Advisors Llc | Sell | 248 819 | Common Stock |
| INSIDER POWER |
|---|
| -12.81 |
| Last 96 transactions |
| Buy: 4 275 597 | Sell: 1 504 628 |
Forecast:
16:00 - $0.704
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.704
Forecast 2: 16:00 - $0.704
Forecast 3: 16:00 - $0.704
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.682 (-5.35% ) |
| Volume | 0.0766 mill |
| Avg. Vol. | 0.228 mill |
| % of Avg. Vol | 33.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GLTO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Latest Press Releases
2023-12-21 16:05:00 - Press Release
Topline Results From Mylox-1 Trial Demonstrate Reduction In Fibrosis Of The Bone Marrow In Patients With Myelofibrosis
Six of ten evaluable myelofibrosis patients who received gb2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating loxl2 as a clinical fibrosis target six of ten evaluable myelofibrosis patients who received gb2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating loxl2 as a clinical fibrosis target
2023-10-23 08:00:00 - Press Release
Galecto Presents Updated Clinical Data At Esmo Congress 2023 And Provides Update On Phase 1b/2a Gallant-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received gb1211 100 mg plus atezolizumab for at least three weeks partial response seen in three of five patients with advanced non-small cell lung cancer who received gb1211 100 mg plus atezolizumab for at least three weeks
2023-09-26 16:01:00 - Press Release
Galecto Announces Plans To Explore Strategic Alternatives
Boston, sept. 26, 2023 (globe newswire) -- galecto, inc. (nasdaq: glto), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
2023-08-31 11:00:00 - Press Release
Galecto To Present At Investor Conferences In September
Boston, aug. 31, 2023 (globe newswire) -- galecto, inc. (nasdaq: glto), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that hans schambye, m.d., ph.d., president and chief executive officer of galecto, will participate in the following september 2023 conferences. management will also be available for one-on-one meetings.
2023-08-15 07:30:00 - Press Release
Galecto Announces Topline Results From Phase 2b Galactic-1 Trial Of Gb0139 For The Treatment Of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases announces next steps for clinical development plan in severe liver diseases
Latest News
2024-02-14 13:01:20 - Zacks Investment Research
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-02-14 06:50:12 - Zacks Investment Research
New Strong Buy Stocks for February 14th
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
2023-09-14 08:15:00 - Seeking Alpha
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative clinical outcomes. Galectin Therapeutics' belapectin, a galectin-3 inhibitor in a phase 3 trial for NASH cirrhosis, is a better value proposition with a strong financial backer and excellent safety profile.
2023-08-31 11:00:00 - GlobeNewsWire
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings.
2023-08-16 09:28:34 - Zacks Investment Research
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
2023-08-15 08:39:00 - Market Watch
Galecto shares drop 65% as biotech halts development of lung-disease treatment
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease. After the treatment, GB0139, failed to meet its primary trial endpoint, Galecto said it will discontinue development and focus instead on treatments for severe liver diseases.
2023-08-15 07:55:02 - Reuters
Galecto to discontinue development of lung disease treatment
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.
2023-07-27 22:02:32 - GuruFocus
ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc
On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnology company based in Denmark. This article provides an in-depth analysis of the transaction, the profiles of both ORBIMED ADVISORS LLC (Trades, Portfolio) and Galecto Inc, and the potential implications of this move on their respective portfolios.
2023-05-30 08:00:00 - GlobeNewsWire
Galecto to Present at the Upcoming Jefferies Healthcare Conference
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D. will present at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023. Management will also be available for one-on-one meetings.
2023-04-13 08:30:00 - GlobeNewsWire
Galecto to Present Two Posters at AACR Annual Meeting 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.